Please Wait.....
Report
Oncology Based In-Vivo CRO Market Report and Forecast 2025-2034
Market Report I 2025-07-29 I 350 Pages I EMR Inc.
The global oncology based in-vivo CRO market size was valued at USD 1.19 Billion in 2024, driven by the development of non-viral delivery systems across the globe. The market is anticipated to grow at a CAGR of 7.90% during the forecast period of 2025-2034 to achieve a value of USD 2.55 Billion by 2034.
Oncology Based In-Vivo CRO: Introduction
Oncology based in-vivo CRO provides specialized services in the field of oncology research. A diverse range of services is provided by this organization in order to support the development of new oncology therapies and treatments. The main services provided by Oncology based In-Vivo CRO are study design, selection and validation of animal model, data collection and analysis, and regulatory compliance, along with dosing and drug administration, and tumor imaging and measurement.
The specialized CROs provide knowledge and experience in the conduct of investigations and tests employing in vivo models, such as animal models, to assess the efficacy and safety of new oncology treatments. Through the use of in vivo tumor models, xenograft and syngeneic models, pharmacokinetic investigations, toxicological analyses, and efficacy studies, in-vivo CROs offer thorough evaluation of potential oncology medications. They aid in finding indicators of therapy response or resistance, helping to test novel cancer therapies, and analyzing how treatments affect tumor growth and metastasis.
Global Oncology based In-Vivo CRO Market Analysis
Expert services are provided by these organizations due to the access they have to advanced technologies and equipment that are required and necessary to conduct in-vivo studies. The expansion of personalized medicine owing to the market growth. By offering preclinical services that promote the development of targeted medicines and ease the discovery and validation of biomarkers, in-vivo CROs are significantly contributing to the advancement of personalized medicine. Additionally, the field of immuno-oncology harnesses the body's immune system to fight cancer has also been witnessing significant growth, leading to further oncology based in-vivo CRO market expansion.
In-Vivo CROs actively conducting preclinical studies to evaluate the efficacy and safety of immunotherapies and combination therapies to support the immuno-oncology research, propelling the oncology based in-vivo CRO market growth. The increased integration of artificial intelligence and machine learning technologies to improve the quality of data analysis, image processing, and predictive modeling are directly contributing to the market growth. In-Vivo CROs are the technologies that enables better interpretation of complex preclinical data and facilitate the identification of novel biomarkers, improving decision-making processes and accelerating drug discovery efforts.
Global Oncology based In-Vivo CRO Market Segmentation
"Oncology Based In-Vivo CRO Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Indication
- Blood Cancer
- Solid Tumors
- Other Indications
Market Breakup by Model
- Syngeneic
- Xenograft
- Patient Derived Xenograft (PDX)
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Oncology based In-Vivo CRO Market Overview
The market for oncology based in-vivo CRO has been witnessing evident growth in the past and is expected to see the growth in coming years as well owing to the increasing prevalence of cancer worldwide. The demand for newly developed therapies that are effective and innovative has increased and has created an emphasis on research and development for these therapies in the oncology filed. The demand for cost-effective and time-efficient drug development procedures has also been a driver for market growth.
In-vivo CROs provide specialised knowledge in creating and using animal models that closely resemble the characteristics of human cancers, enabling the assessment of targeted treatments and individualised treatment plans. This is further aiding the oncology based in-vivo CRO market development.
To ensure that only the highest-quality products are let onto the market, health authorities have established strict regulatory restrictions on pharmaceutical businesses. In-Vivo CROs help these companies adhere to these regulations. In-Vivo CROs assist in ensuring that potential oncology treatments meet the requisite safety and efficacy requirements for further development and clinical trials by conducting preclinical research in accordance with Good Laboratory Practise (GLP) standards which directly contributes to the market growth.
Oncology based In-Vivo CRO Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Crown Bioscience Inc.
- Charles River Laboratories Inc.
- ICON PLC
- Taconic Biosciences Inc.
- Covance Inc.
- Eurofins Scientific
- EVOTEC
- The Jackson Laboratory
- Wuxi AppTec.
- MI Bioresearch Inc.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Oncology Based In-Vivo Cro Market Overview
3.1 Global Oncology Based In-Vivo Cro Market Historical Value (2018-2024)
3.2 Global Oncology Based In-Vivo Cro Market Forecast Value (2025-2034)
4 Global Oncology Based In-Vivo Cro Market Landscape
4.1 Image Guided Surgery: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Image Guided Surgery: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indication
5 Global Oncology Based In-Vivo Cro Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Oncology Based In-Vivo Cro Market Segmentation
6.1 Global Oncology Based In-Vivo Cro Market by Indication
6.1.1 Market Overview
6.1.2 Blood Cancer
6.1.3 Solid Tumors
6.1.4 Other Indications
6.2 Global Oncology Based In-Vivo Cro Market by Model
6.2.1 Market Overview
6.2.2 Syngeneic
6.2.3 Xenograft
6.2.4 Patient Derived Xenograft (PDX)
6.3 Global Oncology Based In-Vivo Cro Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Oncology Based In-Vivo Cro Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Oncology Based In-Vivo Cro Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Oncology Based In-Vivo Cro Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Oncology Based In-Vivo Cro Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Oncology Based In-Vivo Cro Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Crown Bioscience Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Charles River Laboratories Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 ICON PLC
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Taconic Biosciences Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Covance Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Eurofins Scientific
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 EVOTEC
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 The Jackson Laboratory
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Wuxi AppTec.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 MI Bioresearch Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security